Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- Hematology
- Oncology
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Leukemia is a heterogeneous group of hematologic malignancies that arise from the dysfunctional proliferation of developing leukocytes. It is classified as either acute or chronic and as myelocytic or lymphocytic. Treatment depends on the type of leukemia but generally involves chemotherapy. This activity reviews the evaluation and treatment of leukemia and highlights the role of the interprofessional team in evaluating and treating patients with this condition.
- Oncology
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and the sixth most common malignancy in females. The treatment modalities currently used for melanoma include surgery, immunotherapy, targeted therapy, and chemotherapy. This activity highlights the role of interprofessional team in caring for patients with melanoma.
- Oncology
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Worldwide lung cancer has the highest rate of mortality and is the leading cause of cancer deaths. The incidence of lung cancer is approximately equal to its mortality. There are approximately 1.8 million new cases of lung cancer every year globally and over 1.6 million deaths secondary to this. The survival rates for lung cancer are abysmal, in the United States the overall 5-year survival is as low as 18% which is in sharp contrast to the high rates of survival for breast, colon, and prostate cancer at 90, 65 and almost 100% respectively.
- Oncology
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Prostate cancer is the most common cancer in men in the United States and will affect 1 in every 6 men 65 years and older. Fortunately, when detected early, it is very treatable. Long-term follow-up of patients with treated prostate cancer is usually performed by primary care providers. This course will address these questions and more as we discuss the management of metastatic prostate cancer.
- Oncology
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Neuroendocrine neoplasms are rare tumors that display marked heterogeneity with varying natural history, biological behavior, response to therapy and prognosis. Their management is complex and often diagnosed late due to lack of specific symptoms during the early stages of the disease. This activity reviews the management of neuroendocrine tumors and highlights the role of the interprofessional team.
- Oncology
- 3.00 ABIM MOC
- 3.00 AMA PRA Category 1 Credit™
- 3.00 Attendance
$0.00
The 13th Annual Updates in the Treatment and Management of Hematologic Malignancies Highlights from San Diego provides an invaluable educational experience highlighting the latest advances in malignant and non-malignant hematology. Please join us to engage with experts and other healthcare professionals to learn and gain practical insights on current therapies, and innovative treatments.
- Oncology
- 3.00 AMA PRA Category 1 Credit™
- 3.00 Attendance
$0.00
The 13th Annual Updates in the Treatment and Management of Hematologic Malignancies Highlights from San Diego provides an invaluable educational experience highlighting the latest advances in malignant and non-malignant hematology. Please join us and engage with experts to learn and gain practical insights on current therapies, and innovative treatments. Available on-demand, this activity ensures that health care professionals caring for these patients have unlimited access to the latest scientific updates, innovative ideas, and pressing issues in their field.